Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 21Terminated 10Unknown 3Recruiting 3Withdrawn 2Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 8Other hematologic neoplasm 8Dermatologic 8Breast 8Gastrointestinal 7Other solid neoplasm 6Gynecologic 5CNS 4Lymphoid 3Head & Neck 3Sarcoma 2Plasma cell 2Genitourinary 2Tumor-Agnostic 1NET 1Myeloid 1Endocrine 1

Conditions

Lymphoma, Non-Hodgkin 3Multiple Myeloma 2Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 78Vincristine 69obinutuzumab 67Doxorubicin 66Prednisone 65Biopsy 64Magnetic Resonance Spectroscopy 62zanubrutinib 52Lenalidomide 52Dexamethasone 49Methotrexate 43Cytarabine 43blinatumomab 40acalabrutinib 37Immunotherapy, Adoptive 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interleukin-2 × Lymphoid × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03666000 2026-02-02

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Imugene Limited

Phase 1 Recruiting
135 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics, INC.

Phase 1/2 Recruiting
128 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡